Judgment of the General Court of 7 March 2013 - Acino v Commission
(Case T-539/10)
(Medicinal products for human use - Suspension of the placing on the market and withdrawal of medicinal products containing the active ingredient Clopidogrel - Variation of the authorisation to place on the market - Prohibition from placing medicinal products on the market - Regulation (EC) No 726/2004 and Directive 2001/83/EC - Proportionality - Obligation to state reasons)
Language of the case: German
Parties
Applicant: Acino AG, formerly Acino Pharma GmbH (Miesbach, Germany) (represented by: R. Buchner and E. Burk, lawyers)
Defendant: European Commission (represented by: initially by: A. Sipos, G. Wilms, B.-R. Killmann and M. Šimerdová, subsequently by: B.-R. Killmann and M. Šimerdová, acting as Agents)
Re:
Application for annulment of the Commission decisions of 29 March and 16 September 2010 relating to the suspension of the placing on the market of medicinal products for human use containing the active ingredient Clopidogrel manufactured on a certain site, to the withdrawal of batches of those medicinal products from the market, to the variation of the authorisation to place those medicinal products on the market and prohibition from placing them on the market
Operative part of the judgment
The Court:
Rules that it is not necessary to give judgment on the application to the extent that it is directed against Commission Decisions C(2010) 2204 and C(2010) 2208 of 29 March 2010, and against Commission Decisions C (2010) 6429 and C(2010) 6436 of 16 September 2010;
Dismisses the action as to the remainder;
Orders Acino AG to pay the costs.
____________1 - OJ C 30, 29.1.2011.